Literature DB >> 9421877

Two groups of endogenous MMTV related retroviral env transcripts expressed in human tissues.

A Willer1, S Saussele, W Gimbel, W Seifarth, P Kister, C Leib-Mösch, R Hehlmann.   

Abstract

The human genome contains at least 50 copies of the human endogenous retrovirus K (HERV-K) family which is related to the mouse mammary tumor virus (MMTV). Some members have been shown to be transcriptionally active and to have large open reading frames. Using the RT-PCR method we have investigated the HERV-K env transcription pattern in several malignant tissues and in peripheral blood mononuclear cells PBMCs). Samples were derived from chronic myelogenous leukemia (CML), breast cancer, colon cancer, high and low grade non-Hodgkin's lymphomas, Hodgkin's disease, myelodysplastic syndrome, thyroid adenoma (TA) and from PBMCs of patients with breast cancer, gastric cancer, and of healthy individuals. We found abundant HERV-K env transcripts in all tissues under investigation. Using HERV-K 10 specific primers for amplification we detected in addition to transcripts with high homology to HERV-K 10 (ca. 96% homology on the amino acid level) also transcripts of low homology to HERV-K10 (ca. 71%). Interestingly, all solid tissues containing high percentages of malignant cells such as breast cancer, colon carcinoma, low and high grade non-Hodgkin's lymphomas showed exclusively HERV-K env related transcripts with low homology to HERV-K 10. In contrast, in samples containing only a low proportion of malignant cells or no malignant cells at all we observed both types of transcripts. Thus, our data suggest that the expression pattern of HERV-K elements in human cells is very heterogenous and subjected to a complex transcriptional regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421877     DOI: 10.1023/a:1007910924177

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  38 in total

Review 1.  Human endogenous proviruses.

Authors:  E Larsson; N Kato; M Cohen
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

2.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

Authors:  S Benn; R Rutledge; T Folks; J Gold; L Baker; J McCormick; P Feorino; P Piot; T Quinn; M Martin
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

4.  A general method for the identification of transcribed retrovirus sequences (R-U5 PCR) reveals the expression of the human endogenous retrovirus loci HERV-H and HERV-K in teratocarcinoma cells.

Authors:  R Löwer; J Löwer; C Tondera-Koch; R Kurth
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

5.  Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome.

Authors:  M Ono; T Yasunaga; T Miyata; H Ushikubo
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

6.  Altered levels of endogenous retrovirus-like sequence (VL30) RNA during mouse epidermal cell carcinogenesis.

Authors:  K A Han; P Rothberg; M Kulesz-Martin
Journal:  Mol Carcinog       Date:  1990       Impact factor: 4.784

7.  Expression of antigen reactive with a monoclonal antibody to HTLV-1 P19 in salivary glands in Sjögren's syndrome.

Authors:  W G Shattles; S M Brookes; P J Venables; D A Clark; R N Maini
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

Review 8.  HERV-K: the biologically most active human endogenous retrovirus family.

Authors:  R R Tönjes; R Löwer; K Boller; J Denner; B Hasenmaier; H Kirsch; H König; C Korbmacher; C Limbach; R Lugert; R C Phelps; J Scherer; K Thelen; J Löwer; R Kurth
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996

9.  Identification of human endogenous retroviruses with complex mRNA expression and particle formation.

Authors:  R Löwer; K Boller; B Hasenmaier; C Korbmacher; N Müller-Lantzsch; J Löwer; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

10.  Restricted expression of new HERV-K members in human teratocarcinoma cells.

Authors:  M D Li; D L Bronson; T D Lemke; A J Faras
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  5 in total

1.  Autoantibodies to human endogenous retrovirus-K are frequently detected in health and disease and react with multiple epitopes.

Authors:  C A Herve; E B Lugli; A Brand; D J Griffiths; P J W Venables
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses.

Authors:  Ravi P Subramanian; Julia H Wildschutte; Crystal Russo; John M Coffin
Journal:  Retrovirology       Date:  2011-11-08       Impact factor: 4.602

3.  The distribution of insertionally polymorphic endogenous retroviruses in breast cancer patients and cancer-free controls.

Authors:  Julia H Wildschutte; Daniel Ram; Ravi Subramanian; Victoria L Stevens; John M Coffin
Journal:  Retrovirology       Date:  2014-08-12       Impact factor: 4.602

4.  Modulation of human endogenous retrovirus (HERV) transcription during persistent and de novo HIV-1 infection.

Authors:  Michelle Vincendeau; Ingmar Göttesdorfer; Julia M H Schreml; Armand G Ngounou Wetie; Jens Mayer; Alex D Greenwood; Markus Helfer; Susanne Kramer; Wolfgang Seifarth; Kamyar Hadian; Ruth Brack-Werner; Christine Leib-Mösch
Journal:  Retrovirology       Date:  2015-03-24       Impact factor: 4.602

Review 5.  Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?

Authors:  Ronan F Downey; Francis J Sullivan; Feng Wang-Johanning; Stefan Ambs; Francis J Giles; Sharon A Glynn
Journal:  Int J Cancer       Date:  2014-06-17       Impact factor: 7.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.